anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Absorption: Amoxicillin is stable in the presence of gastric acid and is rapidly absorbed after oral administration. The effect of food on the absorption of Amoxicillin from the tablets and suspension of Amoxicillin has been partially investigated; 400 mg and 875 mg formulations have been studied only when administered at the start of a light meal.

Orally administered doses of 250 mg and 500 mg Amoxicillin capsules result in average peak blood levels 1 to 2 hours after administration in the range of 3.5 mcg/mL to 5 mcg/mL and 5.5 mcg/mL to 7.5 mcg/mL, respectively.

Mean Amoxicillin pharmacokinetic parameters from an open, two-part, single-dose crossover bioequivalence study in 27 adults comparing 875 mg of Amoxicillin with 875 mg of Amoxicillin/clavulanate potassium showed that the 875 mg tablet of Amoxicillin produces an AUC0-∞ of 35.4 ± 8.1 mcg•hr/mL and a Cmax of 13.8 ± 4.1 mcg/mL. Dosing was at the start of a light meal following an overnight fast.

Orally administered doses of Amoxicillin suspension, 125 mg/5 mL and 250 mg/5 mL, result in average peak blood levels 1 to 2 hours after administration in the range of 1.5 mcg/mL to 3 mcg/mL and 3.5 mcg/mL to 5 mcg/mL, respectively.

Oral administration of single doses of 400 mg chewable tablets and 400 mg/5 mL suspension of Amoxicillin to 24 adult volunteers yielded comparable pharmacokinetic data:

* Administered at the start of a light meal.  
† Mean values of 24 normal volunteers. Peak concentrations occurred approximately 1 hour after the dose.

Distribution: Amoxicillin diffuses readily into most body tissues and fluids, with the exception of brain and spinal fluid, except when meninges are inflamed. In blood serum, Amoxicillin is approximately 20% protein-bound. Following a 1-gram dose and utilizing a special skin window technique to determine levels of the antibiotic, it was noted that therapeutic levels were found in the interstitial fluid.

Metabolism and Excretion: The half-life of Amoxicillin is 61.3 minutes. Approximately 60% of an orally administered dose of Amoxicillin is excreted in the urine within 6 to 8 hours. Detectable serum levels are observed up to 8 hours after an orally administered dose of Amoxicillin. Since most of the Amoxicillin is excreted unchanged in the urine, its excretion can be delayed by concurrent administration of probenecid [see DRUG INTERACTIONS (7.1)].
First rib stress fractures are uncommon in athletes and diagnosis requires a high degree of clinical suspicion. Diagnostic delay may increase risk of poor healing and long-term complications. Case reports and series describe these injuries primarily in overhead athletes; proposed contributing factors include anatomic susceptibility to stress and repetitive opposing muscular forces. We describe an ice hockey goalie with acute-on-chronic thoracic back pain who was found to have a first rib stress fracture, which to our knowledge is the first reported in this sport. We hypothesize that biomechanical stress from new stick positioning contributed to the injury. Our patient recovered symptomatically with conservative treatment; however, imaging suggested nonunion of the fracture site and possible pseudoarthrosis.
Sensorineural hearing loss (SNHL), characterized by damage to the inner ear or auditory nerve, is a prevalent auditory disorder. This study explores the potential of Castanopsis echinocarpa (CAE) as a therapeutic agent for SNHL. In vivo experiments were conducted using zebrafish and mouse models. Zebrafish with neomycin-induced ototoxicity were treated with CAE, resulting in otic hair cell protection with an EC50 of 0.49 µg/mL and a therapeutic index of 1020. CAE treatment improved auditory function and protected cochlear sensory cells in a mouse model after noise-induced hearing loss (NIHL). RNA sequencing of NIHL mouse cochleae revealed that CAE up-regulates genes involved in neurotransmitter synthesis, secretion, transport, and neuronal survival. Real-time qPCR validation showed that NIHL decreased the mRNA expression of genes related to neuronal function, such as Gabra1, Gad1, Slc32a1, CaMK2b, CaMKIV, and Slc17a7, while the CAE treatment significantly elevated these levels. In conclusion, our findings provide strong evidence that CAE protects against hearing loss by promoting sensory cell protection and enhancing the expression of genes critical for neuronal function and survival.
The invention relates to a preparation method of a vaccine for epidemic encephalitis B, which comprises the processes of cell culture, virus propagation and vaccine preparation. After cells overgrow with a single layer, a seed culture of viruses and a culture solution are inoculated, and the use quantity of the seed culture of the viruses is that every 100cm<2> of cells is inoculated with 1ml of seed culture of the viruses. The culture solution of the viruses mainly comprises 90-95% of MEM culture solution, 3-5% of calf serum and 7.5% of sodium bicarbonate solution the pH of which is regulated to 7.2-7.6. The vaccine is prepared by adding human serum albumin with the final concentration of 0.3% after being clarified and filtered. The invention adopts an SA14-14-2 attenuated strain to produce an encephalitis purified vaccine. Compared with a vaccine produced by a P3 strain, the attenuated strain is safer and more effective. The invention has the advantages that: (1) the attenuated strain is used for preparing the purified vaccine, which has good safety; (2) the inactivation effect of inactivating the viruses by using beta-propiolactone is good, and an inactivator is naturally degraded and has no residue; and (3) the column chromatography purification property is mild, and the injury to the viruses is small.
The aim of the study was to investigate the effects of two different intracanal medicaments used during regenerative endodontic treatment (RET) on periapical MMP-8 in relation to the radiological outcomes of RET. After local anesthesia and rubber dam isolation were provided, disinfection procedures were applied gently in accordance with the current RET protocol of American Association of Endodontics (AAE) on the molar teeth. Periapical tissue fluid samples were taken with paper points placed to protrude 2 mm from the distal root canal tip. Calcium hydroxide \[Ca(OH)2\] was placed in 10 randomly selected teeth and double antibiotic paste (DAP) intracanal medicaments were placed in the other 10 teeth. Fourteen days later in the second session, the final sampling procedure was performed as in the first session. Then, the treatment was completed according to the current RET protocol of AAE and permanent restorations were made. The success of the treatment and its effect on root development were evaluated by comparing the standard radiographs taken at the end of the treatment and 12 months follow up. MMP-8 levels were measured by immunofluorometric assay (IFMA) in the periapical tissue fluid samples. First and second session MMP-8 levels were compared according to the groups of medicaments \[Ca(OH)2 and DAP groups\] placed in the root canals.
The invention discloses a method for expressing an exogenous gene in an animal cell or animal tissue. The method provides a silkworm baculovirus vector for introducing the exogenous gene into a mammal cell or tissue for carrying out gene presentation. The silkworm baculovirus vector comprises a framework vector silkworm baculovirus BmNPV and an expression cassette of the exogenous vector, which is recombined to a framework vector, wherein the expression cassette of the exogenous vector comprises a mammal promoter, the exogenous gene and a terminator. The invention further discloses a method for expressing the exogenous gene in the animal cell or animal tissue. The method comprises the following steps: infecting the constructed silkworm baculovirus vector with an insect host or insect cell; cultivating the infected insect host or insect cell for amplifying the silkworm baculovirus vector; and harvesting and purifying the amplified product. A silkworm baculovirus gene representation vector constructed by adopting the method has the advantages of incapability of amplification, no recombination with an animal cell gene, convenience for large amplification in vitro, high safety and the like.
OBJECTIVES: The aim of this study was to describe the clinical and diagnostic findings and outcome of cats with bicavitary effusion presenting to a referral centre.
METHODS: Medical records of cats presenting with bicavitary effusion were identified and their history, physical examination findings, clinicopathological data, diagnostic imaging findings, aetiology of bicavitary effusions (cardiac disease, neoplasia, infectious disease, sterile inflammatory disease, severe hypoalbuminaemia, trauma, coagulopathy or 'open' if no definitive diagnosis was reached) and outcome were recorded. Cox regression analysis was performed to identify independent predictors of death in cats with bicavitary effusion. Kaplan-Meier curves were generated for survival analysis.
RESULTS: In total, 103 cats with bicavitary effusion were included. Neoplasia and cardiac disease were the most common aetiologies of bicavitary effusion, in 21 (20.4%) and 20 (19.4%) cats, respectively, followed by infectious disease (n = 11, 10.7%), trauma (n = 13, 12.6%), hypoalbuminaemia (n = 6, 5.8%), sterile inflammatory disease (n = 4, 3.9%) and coagulopathy (n = 1, 1.0%). The median survival time for all cats with bicavitary effusion was 3 days. Cats with a neoplastic aetiology had a 2.03 times greater risk of death compared with cats in which no diagnosis was achieved. Neoplasia (P = 0.030) and pedigree breed status (P = 0.016) were independent predictors of death in the multivariable Cox regression model.
CONCLUSIONS AND RELEVANCE: This study highlights that bicavitary effusions in cats generally carry a guarded to poor prognosis, particularly if neoplasia is the underlying aetiology or if the cat is a pedigree breed. Cardiac disease appeared to be associated with a better prognosis, suggesting that assessment for congestive heart failure should be considered early when evaluating cats with bicavitary effusion. The prognosis for cats with feline infectious peritonitis is likely to be markedly improved by the advent of novel antiviral drugs, compared with the historical cohort of cats presented here.
Methods for use in mobilizing triacylglycerol (TAG) in order to elevate apoliprotein B and Very-Low-Density Lipoprotein (VLDL) are described. In some embodiments, the method involves providing betaine in an amount of about 3 gm/kg of body weight per day in order to mobilize TAG. In some embodiments, serum VLDL is elevated as a result of mobilizing hepatic TAG. In some embodiments, the method includes restricting methionine intake to less than about 1 gm/kg of body weight per day. In some embodiments, the method includes feeding L-cysteine at a level of at least about 3 gm/kg of body weight per day. In some embodiments, the method includes feeding choline bitartrate at a level of about 1.25 gm/kg of body weight per day. Mobilizing hepatic TAG is effective to reduce hepatic steatosis.
The present invention concerns a biomarker useful in adoptive cell therapy. The biomarker in question is CD150, otherwise termed SLAM or SLAMF1. Herein we demonstrate that expression of CD150 on tumour infiltrating lymphocytes infusion products correlates with the response rate seen in those patients. High CD150 expression is found on patients who go on to have a complete response and low expression on patients who do not respond to therapy. The invention relates to the use of the biomarker to predict response rate or stratify patients for treatment. It also covers exploitation of this receptor in adoptive cell therapy regimens in general, including but not limited to over expression of the receptor in T-cell populations or isolation of cells expressing CD150 in an effort to increase efficacy.
Nasopharyngeal carcinoma (NPC) is closely linked to Epstein-Barr virus (EBV) infection. Curcumae Rhizoma, a traditional Chinese herb, has shown antitumor effects, primarily through its component curcumol (Cur), which has been shown to reduce NPC cell invasion and migration by targeting nucleolin (NCL) and Epstein-Barr Virus Nuclear Antigen 1 (EBNA1). We constructed an EBV-positive NPC cell model using C666-1 cells and performed transcriptomics studies after treatment with curcumol, which revealed a significant enrichment of ubiquitin-mediated proteolysis, the PI3K-AKT and mTOR signaling pathways, cell cycle and apoptosis involved in tumor invasion and migration. To investigate the importance of NCL and EBNA1 in curcumol-resistant EBV-positive NPC, we performed a multi-omics study using short hairpin NCL (shNCL) and shEBNA1 EBV-positive NPC cells, and the proteomics results showed enrichment in complement and coagulation cascades and ubiquitin-mediated proteolysis signaling pathways. Here, we focused on ubiquitin-conjugating enzyme E2C (UBE2C), which plays an important role in the ubiquitin-mediated proteolysis signaling pathway. In addition, metabolomics revealed that UBE2C is highly associated with 4-Aminobutanoic acid (GABA). In vitro studies further validated the function of the key targets, suggesting that UBE2C plays an important role in NCL and EBNA1-mediated curcumol resistance to nasopharyngeal carcinoma invasion and metastasis.
OBJECTIVE: To investigate adherence to intravascular catheter (IVC) insertion and maintenance guidelines in Chinese tertiary hospitals.
METHODS: A cross-sectional questionnaire survey of adult inpatients with IVC placements was conducted from July to September 2022 in 20 tertiary hospitals in China. One clinical staff member from each department in each hospital was assigned to participate in the survey. Questionnaires were uniformly collected and reviewed after three months.
RESULTS: This study included 1815 cases (62.69%) of central venous catheter, 471 cases (16.27%) of peripherally inserted central catheter, 461 cases (15.92%) of PORT, and 147 cases (5.08%) of haemodialysis catheter insertions. Statistically significant differences in compliance were observed across the four IVC types, specifically in relation to the insertion checklist, standard operating procedure, and insertion environment (P<0.05). Practice adherence during IVC maintenance differed significantly across the four IVC types in aspects such as availability of IVC maintenance verification forms, daily scrubbing of the catheterized patients, and catheter connection methods (P<0.05). A total of 386 (13.34%) patients developed fever, 1086 (37.53%) were treated with therapeutic antibiotics, 16 (0.55%) developed central-line-associated bloodstream infections, two (0.07%) developed local skin infections, and six (0.21%) developed deep vein thrombosis.
CONCLUSIONS: Adherence to guidelines regarding insertion and maintenance differed across the four IVC types; there is a gap between the recommended measures and the actual operation of the guidelines. Therefore, it is necessary to further enhance training and develop checklists to prevent central-line-associated bloodstream infections.
The present invention relates to a cosmetic composition for skin improvement, containing an extract of a Nymphoides sp. plant, and specifically, to a cosmetic composition for skin improvement, containing an extract of a Nymphoides sp. plant, capable of improving skin as the extract of the Nymphoides sp. plant has effects of alleviation of skin inflammation, prevention of skin aging, improvement of skin moisturization, improvement of skin whitening, and alleviation of skin wrinkles. The cosmetic composition according to the present invention contains the extract of the Nymphoides sp. plant as an active ingredient and has such as anti-oxidation, alleviation of skin inflammation, prevention of skin aging, alleviation of skin damage caused by ultraviolet rays, improvement of skin moisturization, improvement of skin whitening, alleviation of skin wrinkles, and the like, thereby remarkably improving skin.
A method for treating cancer includes the steps of: administering to a subject an effective amount of zero valent iron (ZVI) nanoparticles and an effective amount of at least one resistance modulating agent. The shell of each of the ZVI nanoparticles includes gold (Au). The resistance modulating agent includes inducers of programmed cell death, such as erastin, sulfasalazine, sorafenib, buthionine sulfoximine, Ras selective lethal 3 (RSL-3), altretamine, and FIN56. The resistance modulating agent can induce ferroptosis, promote lipid peroxidation, block NADP (H) supply, or suppress metabolism of polyunsaturated fatty acids. Alternatively, the resistance modulating agent can suppress expression of at least one of GSR, AKR1C1, AKR1C3, AKR1B1, AKR1B10 and KYNU genes or promote expression of at least one of ACSL4, ZEB1 and NNMT genes. A method for improving efficacy of a cancer treatment using the ZVI nanoparticles and another method for treating cancer are also provided.
Cutaneous wound healing is a complex biological process involving a series of well-coordinated events aimed at restoring skin integrity and function. Various experimental models have been developed to study the mechanisms underlying skin wound repair and to evaluate potential therapeutic interventions. This review explores the diverse array of skin wound healing models utilized in research, ranging from rodent excisional wounds to advanced tissue engineering constructs and microfluidic platforms. More importantly, the influence of lipids on the wound healing process is examined, emphasizing their role in enhancing barrier function restoration, modulating inflammation, promoting cell proliferation, and promoting remodeling. Lipids, such as phospholipids, sphingolipids, and ceramides, play crucial roles in membrane structure, cell signaling, and tissue repair. Understanding the interplay between lipids and the wound microenvironment provides valuable insights into the development of novel therapeutic strategies for promoting efficient wound healing and tissue regeneration. This review highlights the significance of investigating skin wound healing models and elucidating the intricate involvement of lipids in the healing process, offering potential avenues for improving clinical outcomes in wound management.
STUDY OBJECTIVE: The aim of this quality improvement (QI) project was to assess postoperative narcotic use after pediatric gynecologic surgeries and establish standard postoperative opioid dosing. Through standard dosing, we hoped to decrease variability in postoperative opioid prescriptions and decrease excess opioid doses in the community.
METHODS: This quality improvement project was approved by the Children's Minnesota institutional review board. Counseling on postoperative pain management was provided pre- and postoperatively. At the 2-week postoperative visit, patients were asked about the number of opioid doses used and pain control satisfaction. Baseline data were collected for 6 months, with surgeons prescribing the number of opioid doses on the basis of their personal preference. After reviewing the prescribing practices and number of doses used, standard opioid doses were established, and data collection was repeated.
RESULTS: Complete data were recorded for 30 cases before implementation of standard doses and for 29 cases after implementation. Standardized opioid dosing resulted in a 30% decrease in total opioid doses in circulation (252 to 176 doses; P = .014) and a 15% reduction in excess doses in circulation (162 to 137 doses). Forty-three percent of patients did not use any opioid doses. There was no significant difference (P = .8818) in patient pain control satisfaction rating.
CONCLUSION: Standard opioid dose prescribing is feasible for common pediatric gynecologic surgeries without affecting patient pain control satisfaction. Opioid dose standardization may decrease opioid circulation within the community. Approximately 2 of every 5 patients used 0 opioid doses, which suggests that a further reduction in the standard dose prescriptions is possible.
PROBLEM TO BE SOLVED: To provide a process for producing a vaginal suppository which eliminates the need for a producer and consumer for respectively manually handling the suppository during production process and the dosage and a product which is easy in inserting it into the celom of vaginal celom, etc., and is not need for manually handling before, its inserting. SOLUTION: This applicator 100 consists of a plunger 10, a cylindrical part 20 and the suppository 30. The suppository 30 is formed on site. Namely, the suppository is produced in the unit dose applicator by placing a tubular cartridge into a cartridge holder, packing an aq. compsn. into the tubular cartridge, freezing the compsn. at a temp. between about -20 deg.C and about -40 deg.C, dropping the pressure acting on the frozen aq. compsn. down to the absolute pressure within a range of about 30 to about 1000 micron Hg and drying the compsn. within the tubular cartridge.
Hydration of a larynx and/or vicinity with a composition comprising a divalent salt formulation in conjunction with a substance that promotes or is associated with: a drying out of a mouth and upper airways, a hoarseness, and/or a cough. The composition is administered as dry particles or powder (e.g., aerosol) or as a liquid (e.g., solution or, aerosol). The liquid can have a pH of 7.0 up to around 10.0, or preferably around 7.5 up to around 9.5, or more preferably around 8.0 up to around 9.0, or even more preferably 8.0 to 8.5 or most preferably around 8.0. The droplets can have a mass median aerodynamic diameter from approximately 8 μm to approximately 15 μm or from approximately 20 μm to approximately 500 μm. A therapeutic dose (e.g., 0.5mg to 4.0 mg mass of salt) is administered in response to an indication. Such can employ an osmolitically active composition.
The invention relates to a preparation method and anti-inflammatory application of Vernonia amygdalina Del. ethanol extract active ingredients. The Vernonia amygdalina Del. ethanol extract active ingredients are obtained by crushing Vernonia amygdalina Del. leaves and then performing ethanol extraction. The Vernonia amygdalina Del. ethanol extract active ingredients have the functions of remarkably reducing the contents of CRP, IL-1beta, IL-6, IL-8 and TNF-alpha inflammation factors of acutely inflammatory animals and reducing the perimeter and the volume of ankle joints of the acutely inflammatory animals, have an excellent anti-inflammatory function, can be used for treating or preventing inflammation caused by increasing of the inflammation factors CRP, IL-1beta, IL-6, IL-8 and TNF-alpha.